GERON CORP Effective Income Tax Rate Reconciliation, Tax Credit, Percent
GERON CORP (GERN) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -2.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2026-03-02
- GERON CORP effective income tax rate reconciliation, tax credit, percent for fiscal 2025 was -2.70%.
- GERON CORP effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -2.40%.
- GERON CORP effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was -4.10%.
- GERON CORP effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was -4.90%, a 185.96% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -2.70% 10-K · filed 2026-03-02 | |
| 2024-12-31 | -2.40% 10-K · filed 2026-03-02 | -2.70% 10-K · filed 2025-02-27 |
| 2023-12-31 | -4.10% 10-K · filed 2026-03-02 | 4.10% 10-K · filed 2024-02-28 |
| 2022-12-31 | -4.90% 10-K · filed 2025-02-27 | 4.90% 10-K · filed 2023-03-16 |
| 2021-12-31 | 5.70% 10-K · filed 2024-02-28 | |
| 2020-12-31 | 5.30% 10-K · filed 2023-03-16 | |
| 2019-12-31 | 4.00% 10-K · filed 2022-03-10 | |
| 2018-12-31 | 3.90% 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |